the impact of a genomic assay on urologist treatment preference in active surveillance-eligible men
Published 1 year ago • 129 plays • Length 50:38Download video MP4
Download video MP3
Similar videos
-
8:43
industry perspective: the oncotype dx genomic prostate score assay test
-
20:23
active surveillance criteria and follow-up protocol
-
12:53
the "who's" of genomic markers: who to treat
-
4:34
the role of genomics in newly diagnosed prostate cancer: ashley ross, md, phd
-
18:38
genetics & genomics of prostate cancer – 2023 zero prostate cancer summit
-
4:34
the fear of cancer & choosing active surveillance | ask a prostate expert, mark scholz, md
-
19:15
prostate cancer genetics and genomics
-
2:47
genomic assays impact treatment decisions in patients with er breast cancer
-
8:07
point-counterpoint q&a w/ dr. klein: oncotype dx genomic prostate score in active surveillance
-
11:49
updates in prostate cancer biomarkers
-
5:16
advanced genomic testing at associated urological specialists
-
0:50
breast cancer | abus
-
0:27
is genicular artery embolization safe?
-
1:15
what is urogynecology?
-
42:01
oxford university surgical lectures: genomics of prostate cancer
-
1:02:43
rethinking prostate cancer surveillance and treatment approaches
-
1:32
unlocking the power of integrin signaling in cancer: discovering new therapeutic frontiers
-
41:30
integrating imaging & genomics in the management of prostate cancer - robert reiter, md | uclamdchat
-
3:42
jitc’s original research sections
-
12:30
sequential intravesical gemcitabine and docetaxel for high risk nmibc by max kates
-
13:24
genetics and genomic biomarkers: how molecular markers and mpmri play a role
-
3:46
breann_reinsch_-_genetic_counselingmp4 (original)